Array

Jeff Colyer, M.D.Jeff Colyer, M.D.Jeff Colyer, M.D., has extensive medical and leadership experience as a practicing physician, corporate advisor, Lt. Governor, and Governor of Kansas. He advises government and business on Covid-19, health, and tech as the CEO of Virtus Consultants. Dr. Colyer has served as Assistant Professor at Georgetown University, the University of Kansas Medical School, and the Uniformed Services University for the Health Sciences. He has extensive experience with federal, state and international health policy as a policymaker, elected official and corporate advisor. He led Kansas to be the first state to reform Medicaid into a fully integrated, private system saving $2 billion while improving outcomes. Gov. Colyer has an undergraduate degree from Georgetown University, Washington DC, a masters from Cambridge University, Cambridge UK, and a medical degree from Kansas University.

Ooi Eng Eong, Ph.D., BMBS, FRCPathOoi Eng Eong, Ph.D., BMBS, FRCPathOoi Eng Eong, Ph.D., BMBS, FRCPath, is a Professor and Deputy Director of the Emerging Infectious Diseases Programme at the Duke-NUS Medical School, Singapore. He also holds an appointment as Professor at Saw Swee Hock School of Public Health and Yong Loo Lin School of Medicine, National University of Singapore. Prof Ooi plays a key role in ongoing efforts by Duke-NUS to develop a vaccine for COVID-19 and was instrumental to the Duke-NUS and Arcturus partnership. Dr. Ooi is the recipient of the Clinician-Scientist (Senior Investigator) Award by the National Medical Research Council of Singapore in 2010, 2014 and 2018. Prof Ooi completed his medical studies at the University of Nottingham and thereafter pursued research training in molecular epidemiology under the mentorship of now Emeritus Professor Chan Soh Ha at the Department of Microbiology, National University of Singapore.

Frederick G. Hayden, MD, FACPFrederick G. Hayden, MD, FACPFrederick G. Hayden, MD, FACP, is Stuart S. Richardson Professor Emeritus of Clinical Virology and Professor Emeritus of Medicine at Virginia University School of Medicine. He serves as a consultant to WHO and to multiple academic groups and companies on emerging viral infections. He joined the faculty of the University of Virginia School of Medicine in 1978. Dr. Hayden has served as medical officer in the Global Influenza Program at the World Health Organization and as influenza research coordinator at the Wellcome Trust. His principle research interests have been on respiratory viral infections with a particular focus on the development and application of antiviral agents. He has published over 400 peer-reviewed articles, chapters, and reviews, and co-edits the textbook Clinical Virology. He received his medical degree from Stanford University School of Medicine and clinical training in internal medicine and infectious diseases at Strong Memorial Hospital, University of Rochester.

Peter A. Patriarca, M.D.Peter A. Patriarca, M.D.Peter A. Patriarca, M.D., is the Principal of Immuno-Vax, and a senior affiliate consultant with the Biologics Consulting Group. He has provided technical and regulatory consulting services for all phases of vaccine and drug development, including approximately 400 IND submissions and 12 successful BLAs or NDAs. Prior to consulting, Dr. Patriarca was Corporate Head and Vice President, Worldwide Regulatory Affairs and Pharmacovigilance at MedImmune and also served as Medical Officer in the U.S. Public Health Service at the Centers for Disease Control and Prevention and the US Food and Drug Administration. At FDA, Dr. Patriarca served, among other positions, as Director of the Division of Viral Products in the Office of Vaccines Research and Review, CBER. He has authored more than 100 peer-review publications and has served on multiple scientific advisory bodies for CDC, WHO, the Bill and Melinda Gates Foundation, the American Academy of Pediatrics, the National Academy of Sciences, and numerous pharmaceutical companies.

Robert T. Schooley, M.D.Robert T. Schooley, M.D.Robert T. Schooley, M.D., serves as Professor of Medicine and Senior Director of International Initiatives at the University of California San Diego. His research efforts are directed at the pathogenesis and therapy of RNA virus infections. He has been Head of the Division of Infectious Diseases at the University of Colorado and led the NIH’s AIDS Clinical Trials Group (ACTG) from 1995 until 2002. At the University of California San Diego, he has served as Head of UCSD’s Infectious Diseases Division and now serves as Senior Director of International Initiatives for the University of California San Diego and has become deeply engaged in the University’s response to the SARS CoV-2 outbreak. He completed medical school and an internal medicine residency at Johns Hopkins and infectious disease fellowships at the NIH and Massachusetts General Hospital.

Jonathan Smith, Ph.D.Jonathan Smith, Ph.D.Jonathan Smith, Ph.D., is a molecular virologist and immunologist with 40 years of experience in the development of vaccines and vaccine technologies. He serves at Chief Scientific Officer at VLP Therapeutics. His career has bridged academia, government, and biotech, and in the last 20 years, he has been the CSO of four different biotechnology companies. Dr. Smith has been a pioneer in the design and development of self-amplifying RNA vaccine vectors, and has developed other vaccine technologies from basic research to FDA licensure. He has over 30 issued patents, and over 100 published research papers. Dr. Smith earned his Ph.D. in microbiology / virology from the University of Texas at Austin.

Michael R. Hodges, M.D., BSc.Michael R. Hodges, M.D., BSc.Michael R. Hodges, M.D., BSc. is an infectious disease clinician and RNA medicines drug development executive with 30 years of experience within the biopharmaceutical industry. He is currently Chief Medical Officer (CMO) at Amplyx Pharmaceuticals, developing drug treatments for life-threatening viral and fungal infections in immunocompromised patients. Prior to Amplyx he was the CMO for two RNA platform companies, Santaris A/S and Altair Therapeutics Inc., developing drugs for infectious diseases, cancer, metabolic and respiratory diseases. Previously, he served in Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs. Dr. Hodges earned his M.D. (MBBS) and a BSc. In Pharmacology, from the University of London, UK.

Drew Weissman, M.D., Ph.D.Drew Weissman, M.D., Ph.D.Dr. Weissman, is a professor of Medicine at the Perelman School of Medicine, University of Pennsylvania with over 100 publications and patents. He received his graduate degrees from Boston University School of Medicine. Dr. Weissman co-discovered the ability of modified nucleosides in RNA to suppress activation of innate immune sensors and increase the translation of mRNA containing certain modified nucleosides. Dr. Weissman's laboratory focuses on the study of RNA and innate immune system biology and the application of these findings to vaccine research, protein therapeutics, and gene therapy. He is also an Attending Physician at the Philadelphia Veterans Administration Medical Center, a member of The American Association of Immunologists, and a member of the American Federation for Clinical Research.

News & Events
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
June 1, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 3, 2013
With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego
READ MORE
June 3, 2013
RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round
READ MORE
June 3, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 4, 2013
Janssen Labs-based Arcturus gets $1.3M boost for RNAi delivery tech
READ MORE
June 4, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 4, 2013
Startup Arcturus Pulls in $1.3M in Seed Money amid Renewed Interest in RNAi
READ MORE
August 14, 2013
Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
READ MORE
August 14, 2013
Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina
READ MORE
August 15, 2013
San Diego upstart acquires RNA tech from cash-strapped Marina Biotech
READ MORE
August 15, 2013
San Diego Life Sciences Roundup: Vical, Fate, Arcturus, and More
READ MORE
August 15, 2013
Arcturus Therapeutics Acquires Patent Portfolio from Marina Biotech
READ MORE
August 15, 2013
Marina Sells UNA Patent Estate to Arcturus as It Looks to Resume Operations
READ MORE
October 21, 2013
GenomeWeb Acturus Closes $5M Series A Round, Aims for Clinic in '15 with RNAi Drug
READ MORE
October 21, 2013
RNAi firm raises $5M to develop and deliver drugs that turn off disease-causing genes
READ MORE
October 21, 2013
Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
READ MORE
October 21, 2013
Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
READ MORE
October 22, 2013
San Diego's Arcturus Raises $5M for 'Best-in-Class' RNAi Technology
READ MORE
October 22, 2013
Arcturus Raises $5M in Series A Funding
READ MORE
October 23, 2013
Arcturus rakes in $5M to back RNAi tech, nanoparticle delivery
READ MORE
January 7, 2014
Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
READ MORE
January 13, 2014
Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
READ MORE
January 13, 2014
Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
READ MORE
January 30, 2014
Arcturus Therapeutics to Present at the Keystone Symposia Conference on RNA Silencing
READ MORE
February 24, 2014
Arcturus Therapeutics to Present RNAi Data for Orphan Diseases Utilizing the LUNARTM Technology Platform at BIOCOM's Global Life Science Partnering Conference
READ MORE
February 27, 2014
Arcturus Releases Data Showing Potential of Delivery Technology for CRISPR Drugs
READ MORE
March 10, 2014
Arcturus Therapeutics to Present at the BIO-Europe Spring Partnering Conference
READ MORE
March 27, 2014
Arcturus Therapeutics to Present at the BioCentury Future Leaders in the Biotech Industry Conference
READ MORE
April 7, 2014
Arcturus Therapeutics to Present at the 13th Annual Needham Healthcare Conference
READ MORE
May 6, 2014
Arcturus Therapeutics Appoints Robert Baltera and Stuart Collinson, Ph.D. to its Board of Directors
READ MORE
May 13, 2014
Arcturus Therapeutics Announces Allele-Specific Silencing Technology at IBC’s 16th Annual TIDES Conference
READ MORE
June 23, 2014
Why San Diego is a Hub for RNA R&D and Drug Development
READ MORE
October 13, 2014
Arcturus Therapeutics to Present Gene Knockdown Data in Non-Human Primates, Showing up to 94% Reduction in Gene Expression with a Single Low Dose
READ MORE
October 16, 2014
Arcturus Touts Dosing, Specificity of ATTR Drugs as They Move Toward Clinic
READ MORE
October 23, 2014
Top 30 Life Science Startups To Watch In The U.S.
READ MORE
November 3, 2014
Arcturus Therapeutics expands in La Jolla
READ MORE
November 3, 2014
Arcturus Therapeutics Expands Operations in San Diego, CA
READ MORE
November 10, 2014
Arcturus Therapeutics Presents Preclinical Messenger RNA Data in Non-Human Primates at the 2nd International mRNA Health Conference
READ MORE
November 11, 2014
Arcturus Demonstrates mRNA Delivery to Primates, Sees Possible Rx by 2016
READ MORE
November 12, 2014
Arcturus Presents mRNA Delivery Data Applicable to CF Treatment
READ MORE
November 20, 2014
Arcturus shoots for 'LUNAR' landing in treating rare diseases
READ MORE
December 3, 2014
Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference
READ MORE
December 9, 2014
Arcturus Therapeutics Announces the Appointment of Michael R. Hodges, M.D. to the Scientific Advisory Board
READ MORE
January 7, 2015
Arcturus Therapeutics to Present Messenger RNA Pipeline at the 33rd Annual J.P. Morgan Healthcare Conference and the 7th Annual Biotech Showcase
READ MORE
January 9, 2015
Precision NanoSystems and Arcturus Therapeutics Announce a Partnership for the Manufacture of RNA Medicines
READ MORE
June 11, 2015
Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications
READ MORE
October 11, 2015
2015 Oligonucleotide Therapeutics Society
READ MORE
October 29, 2015
Ultragenyx gives Arcturus rocket shot in potential $1.57B deal
READ MORE
October 29, 2015
Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research Collaboration and License Agreement to Develop RNA Therapeutics for Rare Diseases
READ MORE
November 3, 2015
Arcturus Therapeutics Announces the Appointment of Drew Weissman M.D., Ph.D. to the Scientific Advisory Board
READ MORE
November 11, 2015
International mRNA Health Conference
READ MORE
January 6, 2016
Arcturus Therapeutics Selected to Present at Biotech Showcase™ 2016
READ MORE
March 16, 2016
Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology
READ MORE
June 1, 2016
Arcturus Therapeutics To Present At 2016 BIO International Convention in San Francisco
READ MORE
September 30, 2016
November 1-2, 2016
READ MORE
October 3, 2016
Arcturus Therapeutics to Report Identification of LUNAR-HBV, a Potent Combination of Three UNA Oligomers Targeting All Hepatitis B Virus Genotypes at the AASLD Liver Meeting® 2016
READ MORE
October 4, 2016
Big Pharma Goes Small With Moves Into Incubator Space
READ MORE
November 1, 2016
nature Biotechnology and nature Reviews Drug Discovery
READ MORE
December 6, 2016
Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA–based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
READ MORE
January 7, 2017
East West CEO Conference-Panel Discussion on Mid-Cap Biotech: Challenges and Opportunities
READ MORE
January 24, 2017
Fierce Innovation Awards 2016 Life Science Edition
READ MORE
January 31, 2017
From Incubation to Investment: The Trajectory of Arcturus Therapeutics
READ MORE
February 13, 2017
Arcturus Therapeutics to Present at the 19th Annual Bio CEO and Investor Conference in NY
READ MORE
February 15, 2017
Collaboration between Salk institute (Verma lab) and Arcturus Therapeutics Inc. to treat hemophilia B in mice
READ MORE
February 15, 2017
PNAS Publication on Arcturus and Salk--Systemic delivery of factor IX messenger RNA for protein replacement therapy
READ MORE
February 24, 2017
Arcturus To Attend 8th Annual SBP Rare Disease Day Symposium: Alagille Syndrome - New Research, New Hope
READ MORE
March 1, 2017
Arcturus To Attend Biocom Global Life Science Partnering Conference 2017
READ MORE
March 3, 2017
Arcturus To present at UCSF Rare Disease Symposium: “A New Era of Nucleic Acid Therapeutics to Treat Orphan Diseases”.
READ MORE
March 7, 2017
BioCentury featuring Arcturus Therapeutics in an article called Getting the Message
READ MORE
March 9, 2017
Arcturus To Present at BD Boston Conference
READ MORE
March 10, 2017
Arcturus Therapeutics featured by SCRIP Intelligence publication
READ MORE
March 30, 2017
Arcturus to present at RNA & Oligonucleotide Therapeutics-Cold Spring Harbor Labratory
READ MORE
April 3, 2017
Arcturus to present at the ACS 253rd National Meeting, on Potent delivery of LUNAR™ nanoparticles containing synthetic mRNA for therapeutic protein expression
READ MORE
April 6, 2017
Melinda Richter, Head of Johnson & Johnson Innovation JLABS, highlighting Arcturus in the Nature Reviews Drug Discovery
READ MORE
April 10, 2017
Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego
READ MORE
April 10, 2017
Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego
READ MORE
April 10, 2017
Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego
READ MORE
April 29, 2017
Arcturus Therapeutics to Present at the TIDES--Oligonucleotides and Peptide Therapeutics, on Unlocked Nucleomonomer Agent (UNA) Oligomer System, Challenges and Opportunities
READ MORE
May 15, 2017
Ernst & Young Selected Arcturus as the Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego
READ MORE
May 29, 2017
Boston CEO Conference-Panel Discussion on Advances in Personalized Medicine
READ MORE
May 29, 2017
Boston CEO Conference-Panel Discussion on Advances in Personalized Medicine
READ MORE
June 1, 2017
GEN News Featuring Arcturus Therapeutics on its cover page--in Better Targeting, Delivery of RNAi Therapies
READ MORE
June 16, 2017
Arcturus Therapeutics to Present at 2017 Bio International Convention (Mon June 19th)
READ MORE
June 20, 2017
Xconomy article on Arcturus Therapeutics, Inc.
READ MORE
June 22, 2017
GEN article on Arcturus Therapeutics Inc.
READ MORE
July 6, 2017
Union Tribune article on Arcturus Therapeutics Inc.
READ MORE
July 7, 2017
The Korea Herald News on Arcturus Therapeutics Inc.
READ MORE
July 13, 2017
Arcturus Therapeutics Inc. is Listed in the Key Players List; Involved in Non Alcoholic Steatohepatitis Pipeline (NASH)
READ MORE
August 9, 2017
Arcturus Therapeutics in the list of Cystic Fibrosis Key Companies
READ MORE
August 23, 2017
Pictures by Ernst and Young (Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego)
READ MORE
May 30, 2017
Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR Therapeutic
READ MORE
September 27, 2017
Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge
READ MORE
September 27, 2017
Webcast: Arcturus Merger w/Alcobra Conference Call
READ MORE
October 6, 2017
Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference
READ MORE
October 19, 2017
Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines
READ MORE
October 26, 2017
Arcturus Therapeutics Announces Presentations at Conferences in November
READ MORE
October 30, 2017
Arcturus Therapeutics to Present at the 5th International mRNA Health Conference on Nov 1st
READ MORE
October 30, 2017
Arcturus Therapeutics to Present at the 2017 North American Cystic Fibrosis Conference on Nov 2nd
READ MORE
October 30, 2017
Arcturus Therapeutics to Present at NY/NJ CEO Conference on Nov 8th
READ MORE
October 31, 2017
Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics
READ MORE
November 2, 2017
Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7
READ MORE
November 16, 2017
Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market
READ MORE
November 16, 2017
Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market
READ MORE
December 6, 2017
Arcturus Therapeutics Ltd., to Present at Genetic Rx Conference at Harvard Medical School (Dec 7th), in a Panel Discussion Called “Next Generation RNA Technologies”
READ MORE
May 29, 2018
Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne
READ MORE
May 30, 2018
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
READ MORE
May 31, 2018
Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO
READ MORE
June 18, 2018
Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference
READ MORE
July 9, 2018
Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
READ MORE
July 20, 2018
Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018
READ MORE
July 23, 2018
Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics
READ MORE
August 27, 2018
Arcturus Therapeutics to Present at Three Investor Conferences in September
READ MORE
August 28, 2018
Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer
READ MORE
August 29, 2018
Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor
READ MORE
September 21, 2018
Arcturus Therapeutics Expands Management Team
READ MORE
September 25, 2018
Arcturus Therapeutics to Present at October Investor Conferences
READ MORE
October 1, 2018
Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
READ MORE
November 5, 2018
Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility
READ MORE
November 7, 2018
Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results
READ MORE
December 3, 2018
Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11
READ MORE
January 2, 2019
Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
READ MORE
January 3, 2019
Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer
READ MORE
February 11, 2019
Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency
READ MORE
February 11, 2019
Arcturus Therapeutics to Present at Upcoming Investor Conferences
READ MORE
March 18, 2019
Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results
READ MORE
May 20, 2019
Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics
READ MORE
June 13, 2019
Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation
READ MORE
June 19, 2019
Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases
READ MORE
June 27, 2019
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
READ MORE
July 10, 2019
Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference
READ MORE
August 1, 2019
Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients
READ MORE
August 1, 2019
Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock
READ MORE
August 2, 2019
Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock
READ MORE
August 7, 2019
Arcturus to Report Corporate Overview and Financial Results on August 15
READ MORE
August 15, 2019
Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update
READ MORE
August 26, 2019
Arcturus Therapeutics To Present at Two Investor Conferences in September
READ MORE
September 23, 2019
Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors
READ MORE
September 26, 2019
Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock
READ MORE
October 2, 2019
Arcturus Therapeutics to Present at Three Upcoming Investor Conferences
READ MORE
November 4, 2019
Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th
READ MORE
November 7, 2019
Arcturus Therapeutics Expands Platform with STARR™ Technology
READ MORE
November 7, 2019
Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
READ MORE
January 8, 2020
Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer
READ MORE
February 19, 2020
Arcturus Therapeutics to Present at Two Investor Conferences in March
READ MORE
February 25, 2020
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11
READ MORE
March 4, 2020
Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology
READ MORE
March 27, 2020
Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System
READ MORE
April 9, 2020
Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine
READ MORE
April 13, 2020
Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency
READ MORE
April 15, 2020
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock
READ MORE
April 16, 2020
Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock
READ MORE
April 20, 2020
Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology
READ MORE
April 21, 2020
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
READ MORE
April 27, 2020
Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate
READ MORE
May 4, 2020
Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine
READ MORE
May 5, 2020
Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020
READ MORE
May 7, 2020
Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update
READ MORE
May 8, 2020
Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)
READ MORE
May 21, 2020
Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics
READ MORE
June 5, 2020
Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency
READ MORE
June 11, 2020
Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference
READ MORE
June 29, 2020
Arcturus Therapeutics to be Added to Russell 2000® Index
READ MORE
July 1, 2020
Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board
READ MORE
July 21, 2020
Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19
READ MORE
July 23, 2020
Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19
READ MORE
July 28, 2020
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock
READ MORE
July 29, 2020
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock
READ MORE
August 4, 2020
Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020
READ MORE
August 6, 2020
Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer
READ MORE
August 10, 2020
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update
READ MORE
August 11, 2020
Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study
READ MORE
August 18, 2020
Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health
READ MORE
September 4, 2020
Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate
READ MORE
September 8, 2020
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
October 1, 2020
Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference
READ MORE
October 5, 2020
Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
READ MORE
October 6, 2020
Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate
READ MORE
October 30, 2020
Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020
READ MORE
November 4, 2020
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
November 9, 2020
Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore
READ MORE
November 9, 2020
Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data
READ MORE